14h agoThe FlyBULLISH 62General
Archived explainer. For the current picture see today's ABCL page.
Why Is ABCELLERA BIOLOGICS (ABCL) Stock Up Today?
By the Top Tier Newswire AI Desk · September 30, 2026 at 1:15 AM ET · reviewed against 3 wire stories
ABCELLERA BIOLOGICS (ABCL) is up +6.47% in the latest session. Our newswire has captured 3 stories on ABCL across 2 sources in the last 36 hours, with AI sentiment reading bullish (avg 62/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
ABCL stock rose 6.47% to $14.82 on Tuesday, driven by a new overweight rating from JPMorgan and elevated call volume indicating bullish sentiment. The stock has gained 15.3% over the past eight sessions, reaching a new 52-week high. Recent insider buying and a strong revenue growth trend also contributed to the upward momentum.
What Happened
JPMorgan initiated coverage of AbCellera Biologics with an overweight rating and a $17 price target, according to Benzinga. This marked the first major analyst action on the stock in the past 36 hours. The Fly reported that call volume on the stock was above normal and directionally bullish. Goldman Sachs also reinstated a neutral rating with a $13 price target, but the JPMorgan move appears to have driven the most immediate impact. The stock closed above $14.82, a level that is close to its 52-week high of $14.23.
In addition, AbCellera announced it will present Phase 2 data on ABCL635 at the IMS 20th World Congress on Menopause, a development that could influence investor sentiment in the near term. Recent insider transactions included purchases by the CFO and two directors, with the most recent buy occurring on August 24.
What The Data Shows
The stock has surged 15.3% over the last eight sessions, rising from $12.63 to $14.56. On September 29, the stock printed 10 fresh 52-week highs and one fresh 52-week low. Insider transactions over the past 90 days totaled four buys worth $1.5 million, with no insider sales. The company remains unprofitable, with a trailing twelve-month net margin of -248.8% and an EPS of -0.55. However, revenue increased by 101.3% in the same period. The stock has a beta of 1.32 and a market cap of $4.1 billion.
What To Watch
Investors will want to monitor the presentation of Phase 2 data on ABCL635 at the IMS 20th World Congress on Menopause for potential market reaction. Analyst coverage breadth and any follow-up commentary from JPMorgan or other firms may also influence the stock's trajectory.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
ABCL by the numbers
Last: $14.82Session: +6.47%7 sessions: +15.32%Coverage: 3 stories / 2 sourcesAI sentiment: 62/100 (bullish)Mkt cap: $4.1B52w: $2.75 to $14.23
The headlines behind the move
19h agoInvesting.com Analyst RatingsBULLISH 61Analyst
JPMorgan initiates AbCellera stock coverage with overweight rating
JPMorgan initiates AbCellera stock coverage with overweight rating
23h agoThe FlyBULLISH 63Analyst
AbCellera initiated with an Overweight at JPMorgan
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on ABCL: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier ABCL move explainers: 2026-09-30 · 2026-09-29 · 2026-09-17 · 2026-08-26 · 2026-08-25 · 2026-07-20